Page 58 - Product Testing News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 January 13, 2021 GMT BOSTON--(BUSINESS WIRE)--Jan 13, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the decision to pause further enrollment in the global Phase 3 study of ULTOMIRIS ® (ravulizumab-cwvz) in adults with severe COVID-19 requiring mechanical ventila...

Press release content from Business Wire. The AP news staff was not involved in its creation. AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience January 11, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 11, 2021-- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American S...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ... Helsinn Healthcare S.A.January 12, 2021 GMT Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and ra...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Intercept Appoints Jared M. Freedberg as General Counsel and Secretary Intercept Pharmaceuticals, Inc.January 11, 2021 GMT NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex to Present at the Baader Helvea Swiss Equities Conference Addex TherapeuticsJanuary 12, 2021 GMT Geneva, Switzerland, January 12, 2021 -   Addex Therapeutics  Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development GeoVax, Inc.January 11, 2021 GMT Company Focused on Single-dose Vaccine Against Multiple COVID Strains ATLANTA, GA, Jan. 11, 2021 (GLOBE NEWSWIRE) --   via NewMediaWire  --  GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Business Wire. The AP news staff was not involved in its creation. New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials January 12, 2021 GMT MINNEAPOLIS--(BUSINESS WIRE)--Jan 12, 2021-- OX2 Therapeutics, Inc., a privately held Minneapolis company, announces today that they treated their first patient in a phase one human trial of a new treatment developed to combat recurrent high-grade brain tumors. “This is a first-of-its kind immunotherap...